Entera Bio Ltd.

1.82+0.0700+4.00%Vol 9.23K1Y Perf -64.57%
Aug 5th, 2022 15:37 DELAYED
BID1.82 ASK1.83
Open1.79 Previous Close1.75
Pre-Market- After-Market1.83
 - -  0.01 0.55%
Target Price
6.67 
Analyst Rating
Strong Buy 1.00
Potential %
266.48 
Finscreener Ranking
★★★★★     62.32
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
★★★+     52.50
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
★★★★     59.20
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
11.26 
Earnings Rating
Strong Buy
Market Cap33.19M 
Earnings Date
15th Aug 2022
Alpha-0.02 Standard Deviation0.29
Beta1.81 

Today's Price Range

1.781.83

52W Range

1.315.84

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
-6.19%
1 Month
30.00%
3 Months
-26.02%
6 Months
-20.87%
1 Year
-64.57%
3 Years
-36.14%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ENTX1.820.07004.00
AAPL165.35-0.2300-0.14
GOOG118.22-0.6500-0.55
MSFT282.91-0.7400-0.26
XOM88.451.26001.45
WFC43.760.99002.31
JNJ171.11-0.6800-0.40
FB196.640.99000.51
GE74.360.69000.94
JPM115.763.40003.03
 
ProfitabilityValueIndustryS&P 500US Markets
26.60
-2 845.00
-2 832.60
-
-
RevenueValueIndustryS&P 500US Markets
373.00K
0.02
11.57
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.16-0.1318.75
Q04 2021-0.110.21290.91
Q03 2021-0.10-0.0550.00
Q02 2021-0.10-0.19-90.00
Q01 2021--0.43-
Q03 2020--0.09-
Q02 2020--0.17-
Q01 2020--0.16-
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.1327.78Positive
9/2022 QR-0.1242.86Positive
12/2022 FY-0.6622.35Positive
12/2023 FY-0.7224.21Positive
Next Report Date15th Aug 2022
Estimated EPS Next Report-0.13
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume9.23K
Shares Outstanding18.23K
Shares Float24.20M
Trades Count51
Dollar Volume16.59K
Avg. Volume32.87K
Avg. Weekly Volume29.23K
Avg. Monthly Volume34.80K
Avg. Quarterly Volume34.58K

Entera Bio Ltd. (NASDAQ: ENTX) stock closed at 1.82 per share at the end of the most recent trading day (a 4% change compared to the prior day closing price) with a volume of 9.23K shares and market capitalization of 33.19M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 24 people. Entera Bio Ltd. CEO is Adam Gridley.

The one-year performance of Entera Bio Ltd. stock is -64.57%, while year-to-date (YTD) performance is -35.46%. ENTX stock has a five-year performance of %. Its 52-week range is between 1.31 and 5.84, which gives ENTX stock a 52-week price range ratio of 11.26%

Entera Bio Ltd. currently has a PE ratio of -6.40, a price-to-book (PB) ratio of 2.04, a price-to-sale (PS) ratio of 68.44, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -68.71%, a ROC of -97.68% and a ROE of -101.55%. The company’s profit margin is -%, its EBITDA margin is -2 832.60%, and its revenue ttm is $373.00 Thousand , which makes it $0.02 revenue per share.

Of the last four earnings reports from Entera Bio Ltd., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.13 for the next earnings report. Entera Bio Ltd.’s next earnings report date is 15th Aug 2022.

The consensus rating of Wall Street analysts for Entera Bio Ltd. is Strong Buy (1), with a target price of $6.67, which is +266.48% compared to the current price. The earnings rating for Entera Bio Ltd. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Entera Bio Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Entera Bio Ltd. has a Neutral technical analysis rating based on Technical Indicators (ADX : 31.18, ATR14 : 0.16, CCI20 : 47.22, Chaikin Money Flow : 0.07, MACD : 0.04, Money Flow Index : 65.67, ROC : 20.53, RSI : 43.63, STOCH (14,3) : 69.79, STOCH RSI : 0.89, UO : 52.92, Williams %R : -30.21), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Entera Bio Ltd. in the last 12-months were: Gerald M. Ostrov (Buy at a value of $27 378), Miranda Jayne Toledano (Buy at a value of $18 971), Phillip Schwartz (Buy at a value of $25 250), Ramesh Ratan (Buy at a value of $24 364), Ron Mayron (Buy at a value of $19 600), Sean Ellis (Buy at a value of $52 456), Spiros Jamas (Buy at a value of $28 500), Yonatan Malca (Buy at a value of $19 816)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company which focuses on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical need. The lead oral parathyroid hormone (PTH) product candidate, EB612 for the treatment of hypoparathyroidism. The company also develops a varied oral PTH product candidate, EB613 for the treatment of osteoporosis.

CEO: Adam Gridley

Telephone:

Address: 37 Walnut Street, Wellesley Hills 02481, MA, US

Number of employees: 24

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

53%47%

TipRanks News for ENTX

Wed, 05 Jan 2022 19:05 GMT Entera Bio (ENTX) Receives a Buy from Maxim Group

- TipRanks. All rights reserved.

News

Stocktwits